FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells

Stem Cells

Volumn 29, Issue 2, 2011, Pages 179-192

  Rodriguez, Rene ^a,c   Rubio, Ruth ^a   Gutierrez Aranda, Ivan ^a   Melen, Gustavo J ^a   Elosua, Carolina ^a   García Castro, Javier ^a,b   Menendez, Pablo ^a,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Andalusian Stem Cell Bank   (Spain)

Author keywords

Adipose derived mesenchymal stem stromal cells; FUS CHOP; Fusion genes; Liposarcoma; Mesenchymal stem cells; p53; Sarcomagenesis

Indexed keywords

FUS CHOP FUSION PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYBRID PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GROWTH RATE; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; LIFESPAN; LIPOSARCOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LIPOSARCOMA; MESENCHYMAL STEM CELLS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEIN FUS; TRANSCRIPTION FACTOR CHOP; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 79952121996     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.571     Document Type: Article

References (56)

1. Garcia-Castro J, Trigueros C, Madrenas J et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008;12:2552-2565.
2. Castillero-Trejo Y, Eliazer S, Xiang L et al. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 2005;65:8698-8705. (Pubitemid 41377357)
3. Riggi N, Cironi L, Provero P et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65:11459-11468. (Pubitemid 41821703)
4. Riggi N, Cironi L, Provero P et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006;66:7016-7023. (Pubitemid 44197677)
5. Ren YX, Finckenstein FG, Abdueva DA et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008;68:6587-6597.
6. Suva ML, Riggi N, Stehle JC et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009;69:1776-1781.
7. Riggi N, Suva ML, Suva D et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68:2176-2185. (Pubitemid 351521790)
8. Matushansky I, Hernando E, Socci ND et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 2008;172:1069-1080. (Pubitemid 351520003)
9. Mack TM. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer 1995;75:211-244.
10. Crozat A, Aman P, Mandahl N et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363:640-644. (Pubitemid 23227627)
11. Sanchez-Garcia I, Rabbitts TH. Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA 1994;91:7869-7873.
12. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992;6:439-453.
13. Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 1994;8:2513-2526. (Pubitemid 24347243)
14. Perez-Losada J, Pintado B, Gutierrez-Adan A et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000;19:2413-2422. (Pubitemid 30323474)
15. Bueno C, Montes R, Garcia-Castro J et al. Human embryonic stem cells: A potential system for modeling infant leukemia harboring MLL-AF4 fusion gene. Drug Discov TodayDis Models 2008;4:53-60.
16. Armesilla-Diaz A, Elvira G, Silva A. p53 regulates the proliferation, differentiation and spontaneous transformation of mesenchymal stem cells. Exp Cell Res 2009;315:3598-3610.
17. Berman SD, Calo E, Landman AS et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 2008;105:11851-11856.
18. Lin PP, Pandey MK, Jin F et al. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009;30:1789-1795.
19. Rodriguez R, Rubio R, Masip M et al. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia 2009;11:397-407.
20. Rubio R, Garcia-Castro J, Gutierrez-Aranda I et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 2010;70:4185-4194.
21. Cordon-Cardo C, Latres E, Drobnjak M et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799. (Pubitemid 24068339)
22. Oda Y, Yamamoto H, Takahira T et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 2005;207:410-421.
23. Menendez P, Catalina P, Rodriguez R et al. Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 2009;206:3131-3141.
24. Szulc J, Wiznerowicz M, Sauvain MO et al. A versatile tool for conditional gene expression and knockdown. Nat Methods 2006;3:109-116. (Pubitemid 43173309)
25. Rodriguez R, Hansen LT, Phear G et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin Cancer Res 2008;14:5476-5483.
26. Catalina P, Cobo F, Cortes JL et al. Conventional and molecular cytogenetic diagnostic methods in stem cell research: A concise review. Cell Biol Int 2007;31:861-869. (Pubitemid 46819072)
27. Catalina P, Montes R, Ligero G et al. Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? Mol Cancer 2008;7:76.
28. Montes R, Ligero G, Sanchez L et al. Feeder-free maintenance of hESCs in mesenchymal stem cell-conditioned media: Distinct requirements for TGF-beta and IGF-II. Cell Res 2009;19:698-709.
29. Rodriguez R, Gagou ME, Meuth M. Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45. Cell Death Differ 2008;15:889-898. (Pubitemid 351524431)
30. Bueno C, Montes R, de la Cueva T et al. Intra-bone marrow transplantation of human CD34(+) cells into NOD/LtSz-scid IL-2rgamma (null) mice permits multilineage engraftment without previous irradiation. Cytotherapy 2010;12:45-49.
31. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 2010;28:1568-1570.
32. Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G et al. Embryonic stem cell-specific miR302-367 cluster: Human gene structure and functional characterization of its core promoter. Mol Cell Biol 2008;28:6609-6619.
33. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006;4:263-273. (Pubitemid 44430910)
34. Sekiya I, Larson BL, Vuoristo JT et al. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res 2004;19:256-264. (Pubitemid 38116739)
35. Perez-Mancera PA, Bermejo-Rodriguez C, Sanchez-Martin M et al. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. Plos One 2008;3:e2569.
36. Bagnato A, Spinella F, Rosano L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 2008;86:473-484.
37. Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: Involvement in tumor progression. Int J Oncol 2005;27:1329-1339.
38. Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007;117:3248-3257. (Pubitemid 350096982)
39. Engstrom K, Willen H, Kabjorn-Gustafsson C et al. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 2006;168:1642-1653.
40. Staszkiewicz J, Gimble JM, Manuel JA et al. IFATS collection: Stem cell antigen-1-positive ear mesenchymal stem cells display enhanced adipogenic potential. Stem Cells 2008;26:2666-2673.
41. Ziouzenkova O, Plutzky J. Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPARRXR complex. FEBS Lett 2008;582:32-38. (Pubitemid 50019948)
42. Nanbu-Wakao R, Fujitani Y, Masuho Y et al. Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells. Mol Endocrinol 2000;14:307-316. (Pubitemid 32295399)
43. Xu F, Yang CC, Gomillion C et al. Effect of ceramide on mesenchymal stem cell differentiation toward adipocytes. Appl Biochem Biotechnol 2010;160:197-212.
44. Baird K, Davis S, Antonescu CR et al. Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res 2005;65:9226-9235. (Pubitemid 41507988)
45. Singer S, Socci ND, Ambrosini G et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626-6636. (Pubitemid 47105508)
46. Thelin-Jarnum S, Goransson M, Burguete AS et al. The myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies. Int J Cancer 2002;97:446-450. (Pubitemid 34027802)
47. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001;20:6731-6741. (Pubitemid 33020602)
48. Aguilar S, Nye E, Chan J et al. Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 2007;25:1586-1594. (Pubitemid 47106029)
49. Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371-379. (Pubitemid 46232791)
50. Funes JM, Quintero M, Henderson S et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA 2007;104:6223-6228. (Pubitemid 47186076)
51. Carlson SG, Fawcett TW, Bartlett JD et al. Regulation of the C/EBP-related gene gadd153 by glucose deprivation. Mol Cell Biol 1993;13:4736-4744.
52. Wang XZ, Kuroda M, Sok J et al. Identification of novel stress-induced genes downstream of chop. EMBO J 1998;17:3619-3630. (Pubitemid 28327380)
53. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006;7:885-896. (Pubitemid 44871415)
54. Lee N, Smolarz AJ, Olson S et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 2007;97:1552-1559. (Pubitemid 350175854)
55. Gregory CA, Singh H, Perry AS et al. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 2003;278:28067-28078. (Pubitemid 36900004)
56. Bunney TD, Katan M. Phosphoinositide signalling in cancer: Beyond PI3K and PTEN. Nat Rev Cancer 2010;10:342-352.